Histiocytosis Treatment Market Size & Share, by Type (Langerhans Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis, Malignant Histiocytic Disorders); Drugs (Emapalumab, Alemtuzumab, Infiximab); End User (Hospitals, Homecare, Specialty Clinics, Oncologist, Immunologist) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5489
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Companies Dominating the Histiocytosis Treatment Market

top-features-companies
    • Swedish Orphan Biovitrum AB
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AB2 Bio Ltd.
    • Alpine Immune Sciences.
    • Bellicum Phamaceuticals, Inc.
    • Xencor
    • TG Therapeutics, Inc.
    • Affimed GmbH
    • F. Hoffmann-La Roche Ltd
    • Mereo Biopharma Group PLC
    • Innovent

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • For the treatment of adult patients with histiocytic neoplasms, such as Langerhans cell histiocytosis, Rosai-Dorfman disease, and Erdheim-Chester disease, the FDA has approved cobimetinib (Cotellic).
  • Dabrafenib (Tafinlar) and trametinib (Mekinist), two targeted medications, were recently approved by the Food and Drug Administration (FDA) for the treatment of almost any kind of advanced solid tumour with a certain mutation in the BRAF gene.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5489
  • Published Date: Jan 03, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are the surge in the adoption of telemedicine, the rise in use of big data & AI, and growth in government initiatives.

The market size of histiocytosis treatment is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.

The major players in the market are Swedish Orphan Biovitrum AB, AB2 Bio Ltd., Alpine Immune Sciences., Bellicum Phamaceuticals, Inc., and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying